Volume 22, Number 4—April 2016
Dispatch
Cross-Neutralization between Human and African Bat Mumps Viruses
Table
Serum sample no. | Patient age, y | Mumps history |
EIA titer‡ | NT titer† |
||||
---|---|---|---|---|---|---|---|---|
Natural Infection | Vaccinated | rOdate | rOdate/ABMuV-F | rOdate/ABMuV-HN | rOdate/ABMuV-FHN | |||
1 | 32 | Unknown | + | 22.35 | 121 | 36 | 133 | 122 |
2 | 40 | Unknown | – | 21.36 | 21 | 38 | 78 | 109 |
3 | 49 | Unknown | – | 22.09 | 26 | 7 | 31 | 12 |
4 | 48 | + | – | 22.94 | 176 | 122 | 183 | 149 |
5 | 58 | + | – | 22.80 | 41 | 31 | 41 | 33 |
6 | 56 | + | – | 22.55 | 31 | 8 | 85 | 27 |
7 | 40 | Unknown | – | 21.84 | 88 | 105 | 58 | 33 |
8 | 35 | + | – | 23.32 | 186 | 60 | 131 | 118 |
9 | 33 | Unknown | – | 22.48 | 83 | 30 | 81 | 37 |
10 | 31 | + | – | 22.78 | 53 | 5 | 122 | 26 |
11 | 18 | Unknown | – | 20.74 | <4 | <4 | <4 | <4 |
12 | 18 | Unknown | – | 20.64 | <4 | <4 | <4 | <4 |
*ABMuV, African bat mumps virus; EIA, enzyme immunoassay; F, fusion; HN, hemagglutinin-neuraminidase; NT, neutralizing; r, recombinant; +, positive; –, negative.
†NT titer was determined as the dilution of serum that gave 50% plaque reduction compared with the average number of plaques formed in the absence of serum using the method of Reed and Muench.
‡Determined by using a commercially available indirect IgG eEIA kit (Mumps IgG-EIA kit; Denka Seiken Co., Niigata, Japan) according to the manufacturer’s instruction. Titers <21 are seronegative, 21–22 are indeterminate, and >22 are seropositive.
Page created: March 16, 2016
Page updated: March 16, 2016
Page reviewed: March 16, 2016
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.